Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Forum on Immunopathological Diseases and Therapeutics

ISSN Print: 2151-8017
ISSN Online: 2151-8025

Archives: Volume 1, 2010 to Volume 7, 2016

Forum on Immunopathological Diseases and Therapeutics

DOI: 10.1615/ForumImmunDisTher.2015014073
pages 7-23

CD20 and Its Antibodies: Past, Present, and Future

Robert J. Oldham
The Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton, Faculty of Medicine, General Hospital, Southampton, SO16 6YD, UK.
Kirstie L.S. Cleary
The Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton, Faculty of Medicine, General Hospital, Southampton, SO16 6YD, UK.
Mark S. Cragg
The Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton, Faculty of Medicine, General Hospital, Southampton, SO16 6YD, UK.

ABSTRACT

The pan B-cell marker CD20 was cloned more than 3 decades ago. It has been intensively studied ever since, allowing the specific identification and targeting of B cells facilitating the development of antibody-mediated immunotherapy. In this review, we document the current understanding of how CD20 regulates B-cell biology. We also describe the emerging knowledge of how anti-CD20 antibodies elicit their therapeutic responses, revealing how this has changed and matured throughout the decades of their use.